Matrix therapy with RGTA OTR4120 improves healing time and quality in hairless rats with deep second-degree burns

Plastic and Reconstructive Surgery

Volumn 127, Issue 2, 2011, Pages 541-550

  Zakine, Gilbert ^a,b   Barbier, Véronique ^a   Garcia Filipe, Stéphanie ^a   Luboinski, Jacqueline ^a   Papy Garcia, Dulce ^a   Chachques, Juan Carlos ^a   Carpentier, Alain ^a   Barritault, Denis ^a  

^a Trousseau Hospital ^*

^b SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMIMETIC MATERIAL; GLYCOSAMINOGLYCAN; OTR4120; PROTEOHEPARAN SULFATE;

ANIMAL; ARTICLE; BURN; DISEASE MODEL; DRUG EFFECT; EPIDERMIS; EXTRACELLULAR MATRIX; FEMALE; KERATINOCYTE; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; RAT STRAIN; REGENERATION; WOUND HEALING;

ANIMALS; BIOMIMETIC MATERIALS; BURNS; DISEASE MODELS, ANIMAL; EPIDERMIS; EXTRACELLULAR MATRIX; FEMALE; GLYCOSAMINOGLYCANS; HEPARAN SULFATE PROTEOGLYCANS; KERATINOCYTES; NECROSIS; RATS; RATS, INBRED STRAINS; REGENERATION; WOUND HEALING;

EID: 79951610745     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e318200a910     Document Type: Article

References (46)

1. Robson MC. Growth factors as wound healing agents. Curr Opin Biotechnol. 1991;2:863-867.
2. McGrath MH. Peptide growth factors and wound healing. Clin Plast Surg. 1990;17:421-432. (Pubitemid 20321234)
3. Clark RAF. Wound repair. In:The Molecular and Cellular Biology of Wound Repair. 2nd ed. New York: Plenum; 1996.
4. Rumalla VK, Borah GL. Cytokines, growth factors, and plastic surgery. Plast Reconstr Surg. 2001;108:719-733. (Pubitemid 32781226)
5. Zakine G. Growth factors, modulating growth factors and burn (in French). Burns 2005;6:8-17.
6. Shukla A, Dubey MP, Srivastava R, Srivastava BS. Differential expression of proteins during healing of cutaneous wounds in experimental normal and chronic models. Biochem Biophys Res Commun. 1998;244:434-439. (Pubitemid 28414100)
7. Breuing K, Andree C, Helo G, Slama J, Liu PY, Eriksson E. Growth factors in the repair of a partial thickness porcine skin wounds. Plast Reconstr Surg. 1997;100:657-664. (Pubitemid 27381071)
8. Cribbs RK, Luquette MH, Besner GE. Acceleration of partialthickness burn wound healing with topical application of heparin-binding EGF-like growth factor (HB-EGF). J Burn Care Rehabil. 1998;19:95-101. (Pubitemid 28173455)
9. Danilenko DM, Ring BD, Tarpley JE, et al. Growth factors in porcine full and partial thickness burn repair: Differing targets and effects of keratinocyte growth factor, platelet-derived growth factor-BB, epidermal growth factor, and neu differentiation factor. Am J Pathol. 1995;147:1261-1277.
10. Tardieu M, Gamby C, Avramoglou T, Josefonvicz J, Barritault D. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. J Cell Physiol. 1992;150:194-203.
11. Ledoux D, Papy D, Escartin Q, et al. Human plasmin enzymatic activity is inhibited by chemically modified dextrans. J Biol Chem. 2000;275:29383-29390. (Pubitemid 32043811)
12. Meddahi A, Lemdjabar H, Caruelle JP, Barritault D, Hornebeck W. FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. Int J Biol Macromol. 1996;18:141-145. (Pubitemid 26070478)
13. Desgranges P, Barbaud C, Caruelle JP, Barritault D, Gautron J. A substituted dextran enhances muscle fiber survival and regeneration in ischemic and denervated rat EDL muscle. FASEB J. 1999;13:761-766. (Pubitemid 29156407)
14. Zakine G, Martinod E, Fornes P, et al. Growth factors improve latissimus dorsi muscle vascularization and trophicity after cardiomyoplasty. Ann Thorac Surg. 2003;75:549-554. (Pubitemid 36184508)
15. Blanquaert F, Saffar JL, Colombier ML, Carpentier G, Barritault D, Caruelle JP. Heparan-like molecules induce the repair of skull defects. Bone 1995;17:499-506. (Pubitemid 26017568)
16. Garcia-Filipe S, Barbier-Chassefiere V, Alexakis C, et al. RGTA OTR4120, a heparan sulfate mimetic, is a possible long-term active agent to heal burned skin. J Biol Mater Res A 2007;80:75-84. (Pubitemid 44913335)
17. Barbier-Chassefière V, Garcia-Filipe S, Yue Xl, et al. Matrix therapy and regenerative medicine, a new approach for chronic wound healing. J Biomed Mater Res A 2009;90:641-647.
18. Tong M, Zbinden MM, Hekking IJ, Vermeij M, Barritault D, van Neck JW. RGTA OTR 4120, a heparan sulphate proteoglycan mimetic, increases wound breaking strength and vasodilatory capability in healing rat full-thickness excisional wounds. Wound Repair Regen. 2008;16:294-299. (Pubitemid 351342137)
19. Khammari Chebbi C, Kichenin K, Amar N, et al. Pilot study of a new matrix therapy agent (RGTA OTR4120) in treatment- resistant corneal ulcers and corneal dystrophy (in French). J Fr Ophtalmol. 2008;31:465-471.
20. Zawacki BE. Reversal of capillary stasis and prevention of necrosis in burns. Ann Surg. 1974;180:98-102.
21. Jackson D. The diagnosis of the depth of burning. Br J Surg. 1953;40:588-596.
22. Sullivan TP, Eaglstein WH, Davis SC, Mertz P. The pig as a model for human wound healing. Wound Repair Regen. 2001; 9:66-76. (Pubitemid 32463294)
23. Matsumura H, Yoshizawa N, Kimura T, Watanabe K, Gibran NS, Engrav L. A burn wound healing model in the hairless descendant of the Mexican hairless dog. J Burn Care Rehabil. 1997;18:306-312. (Pubitemid 27329064)
24. Fuchs E, Green H. Changes in keratin gene expression during terminal differentiation of the keratinocyte. Cell 1980; 19:1033-1042. (Pubitemid 10155237)
25. Lloyd C, Yu C, Cheng J, et al. The basal keratin network of stratified squamous epithelia: Defining K15 function in the absence of K14. J Cell Biol. 1995;129:1329-1344.
26. Coulombe PA, Hutton ME, Letai A, Hebert A, Paller AS, Fuchs E. Point mutation in human keratin 14 genes of epidermolysis bullosa simplex patients: Genetic and functional analyses. Cell 1991;66:1301-1311. (Pubitemid 121001418)
27. Desgranges P, Caruelle JP, Carpentier G, Barritault D, Tardieu M. Beneficial use of fibroblast growth factor 2 and RGTA, a new family of heparan mimics, for endothelialization of PET prostheses. J Biomed Mater Res. 2001;58:1-9. (Pubitemid 32150695)
28. Morvan FO, Baroukh B, Ledoux D, et al. An engineered biopolymer prevents mucositis induced by 5-fluorouracil in hamsters. Am J Pathol. 2004;164:739-746. (Pubitemid 38364687)
29. Escartin Q, Lallam-Laroye C, Barouck B, et al. A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers. FASEB J. 2003;17:644-651. (Pubitemid 37221149)
30. Yamauchi H, Desgranges P, Lecerf L, et al. New agents for the treatment of infarcted myocardium. FASEB J. 2000;14:2133-2134.
31. Rouet V, Hamma-Kourbali Y, Petit E, et al. A synthetic glycosaminoglycan mimetic binds vascular endothelial growth factor and modulates angiogenesis. J Biol Chem. 2005;280: 32792-32800. (Pubitemid 41368326)
32. Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of acid fluid. Science 1983; 219:983-985.
33. Connolly DT, Heuvelman D, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989;84:1470-1478. (Pubitemid 19272234)
34. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235:442-447. (Pubitemid 17009577)
35. Hebda PA, Klingbeil CK, Abraham JA, Fiddes JC. Basic fibroblast growth factor stimulation of epidermal wound healing in pigs. J Invest Dermatol. 1990;95:626-631.
36. Gospodarowicz D, Neufeld G, Schweigerer L. Fibroblast growth factor: Structural and biological properties. J Cell Physiol Suppl. 1987;Suppl 5:15-26. (Pubitemid 18012921)
37. Greenhalgh DG, Sprugel KH, Murray MJ, Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol. 1990;136:1235-1246. (Pubitemid 20210322)
38. Fu XB, Shen Z, Chen Y, et al. Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns. Lancet 1998; 352:1661-1664. (Pubitemid 28526124)
39. Fu XB, Shen Z, Chen Y, et al. Recombinant bovine basic fibroblast growth factor accelerates wound healing in patients with burns, donor sites and chronic dermal ulcers. Chin Med J. 2000;113:367-371. (Pubitemid 30241514)
40. Staiano-Coico L, Krueger JG, Rubin JS, et al. Human keratinocyte growth factor effects in a porcine model of epidermal wound healing. J Exp Med. 1993;178:865-878. (Pubitemid 23260424)
41. Jimenez PA, Rampy MA. Keratinocyte growth factor-2 accelerates wound healing in incisional wounds. J Surg Res. 1999; 81:238-242. (Pubitemid 29397817)
42. Soler PM, Wright TE, Smith PD, et al. In vivo characterization of keratinocyte growth factor-2 as a potential wound healing agent. Wound Repair Regen. 1999;7:172-178. (Pubitemid 29331921)
43. Heldin CH, Westermark B. Platelet-derived growth factor mechanism of action and possible in vivo function. Cell Regul. 1990;1:555-566.
44. Brown RL, Breeden MP, Greenhalgh DG. PDGF and TGF-α act synergistically to improve wound healing in the genetically diabetic mouse. J Surg Res. 1994;56:562-570. (Pubitemid 24222406)
45. Pierce GF, Tarpley JE, Tseng J, et al. Detection of plateletderived growth factor (PDGF)-AA in actively healing human wounds treated with recombinant PDGF-BB and the absence of PDGF in chronic nonhealing wounds. J Clin Invest. 1995; 96:1336-1350.
46. Sporn MB, Roberts AB. A major advance in the use of growth factors to enhance wound healing. J Clin Invest. 1993;92: 2565-2566. (Pubitemid 24006516)